Nasdaq

European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types

Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5 Tecentriq SC ...
Nasdaq

Roche (RHHBY) Tecentriq SC Receives Positive CHMP Opinion

Roche RHHBY announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has recommended the approval of the SC formulation of Tecentriq, the immuno-oncology ...
Seeking Alpha

Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) ("Halozyme") today announced the approval of Roche's Tecentriq ® SC (atezolizumab), using Halozyme's ENHANZE ® drug delivery ...